ACVR1 and B-cell non-Hodgkin lymphoma: In summary, our results suggest that PRC2 inhibitors in B‐cell lymphoma treatment induce the upregulation of lineage differentiation, interferons and immune synapse genes, along with the activation of BMP6/7‐ACVR1 signaling, leading to proliferation block and apoptosis to render their anti‐lymphoma efficacy.